Abstract:One receptor, DDR2, both promotes the differentiation of bone-depositing cells and prevents the differentiation of bone-resorbing cells. Reorganizing receptor complexes to rebuild bone The skeleton undergoes continuous turnover mediated by osteoblasts and osteoclasts, which respectively deposit and resorb bone. When this turnover is dysregulated, skeletal diseases such as osteoporosis—a disease characterized by bone loss—can occur. The receptor tyrosine kinase DDR2 (discoidin domain receptor 2) tilts the balance in favor of bone formation. Zhang et al. determined that, in addition to promoting osteoblast differentiation, DDR2 inhibited osteoclast differentiation and bone matrix resorption in culture. In a mouse model of osteoporosis, viral-mediated delivery of DDR2 increased bone density. By forming a complex with the receptors Neuropilin-1 and PlexinA1, DDR2 blocked PlexinA1-mediated stimulation of osteoclastogenesis. Thus, increasing the abundance of DDR2 in both types of bone precursor cells may be therapeutically beneficial for osteoporosis patients. Osteoporosis is a disease characterized by abnormal skeletal fragility due to an imbalance in bone homeostasis. Finding therapeutic targets that promote bone formation is valuable for treating osteoporosis. Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase that promotes the differentiation of bone-depositing cells, osteoblasts, and bone formation. We investigated the role of DDR2 in osteoclastogenesis, the formation of cells responsible for bone resorption. We found that, although differentiated osteoclasts had catalytically active DDR2, its abundance was decreased. Overexpression of DDR2 inhibited the expression of osteoclastic markers, osteoclast maturation, and osteoclast-mediated bone resorption in a culture model of bone matrix. Conversely, knocking down Ddr2 through RNA interference accelerated osteoclast differentiation and bone resorption in mice. Further, we identified the co-receptor Neuropilin-1 (Nrp1) as a DDR2-interacting protein. DDR2 facilitated the binding of Nrp1 and the co-receptor PlexinA1 by forming a DDR2-Nrp1-PlexinA1 complex, which blocked PlexinA1-mediated stimulation of osteoclastogenesis. DDR2 prevented PlexinA1 from interacting with the receptor TREM2 and the adaptor DAP12. Moreover, knocking down Nrp1 rescued the expression of osteoclastic markers observed in DDR2-overexpressing cells, whereas ectopic expression of Nrp1 in DDR2-silenced cells inhibited the induction of osteoclastogenesis. Nrp1 enhanced the function of DDR2 in promoting osteoblast differentiation and bone formation in mice. In an ovariectomized mouse model of osteoporosis, adenovirus-mediated delivery of DDR2 to the femur bone alleviated osteopenic phenotypes. Our results revealed that DDR2 functions as an inhibitor of osteoclastogenesis, as well as a promoter of osteoblastogenesis, suggesting that enhancing DDR2 may be therapeutic for patients with osteoporosis.

NDR2 is Critical for the Osteoclastogenesis by Regulating ULK1-mediated Mitophagy.

Naked cuticle homolog 2 controls the differentiation of osteoblasts and osteoclasts and ameliorates bone loss in ovariectomized mice

N-myc Downstream Regulated Gene 1 Suppresses Osteoblast Differentiation Through Inactivating Wnt/β-catenin Signaling

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

ULK1 Suppresses Osteoclast Differentiation and Bone Resorption Via Inhibiting Syk-JNK Through DOK3

NDRG2 expression suppresses osteoclast differentiation by down-regulating PU.1 (167.6)

The Deubiquitinase UCHL1 Negatively Controls Osteoclastogenesis by Regulating TAZ/NFATC1 Signalling

Nrp1, a Neuronal Regulator, Enhances DDR2-ERK-Runx2 Cascade in Osteoblast Differentiation via Suppression of DDR2 Degradation.

Notopterol Attenuates Estrogen Deficiency-Induced Osteoporosis <i>via</i> Repressing RANKL Signaling and Reactive Oxygen Species

CNC-bZIP protein NFE2L1 regulates osteoclast differentiation in antioxidant-dependent and independent manners

DDR2 (discoidin domain receptor 2) suppresses osteoclastogenesis and is a potential therapeutic target in osteoporosis

LncRNA AK077216 promotes RANKL‐induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45

PERK controls bone homeostasis through the regulation of osteoclast differentiation and function

The Cytoplasmic Dynein Associated Protein NDE1 Regulates Osteoclastogenesis by Modulating M-CSF and RANKL Signaling Pathways

REGγ is Essential to Maintain Bone Homeostasis by Degrading TRAF6, Preventing Osteoporosis

Ubiquitin E3 Ligase LNX2 is Critical for Osteoclastogenesis In Vitro by Regulating M-CSF/RANKL Signaling and Notch2

PDK2 Deficiency Prevents Ovariectomy‐Induced Bone Loss in Mice by Regulating the RANKL‐NFATc1 Pathway During Osteoclastogenesis

Nrf2 Mitigates RANKL and M-CSF Induced Osteoclast Differentiation via ROS-Dependent Mechanisms

Ablation of Discoidin Domain Receptor 1 Provokes an Osteopenic Phenotype by Regulating Osteoblast/Osteocyte Autophagy and Apoptosis

Unraveling the intricacies of osteoclast differentiation and maturation: insight into novel therapeutic strategies for bone-destructive diseases

NDR1/FBXO11 promotes phosphorylation-mediated ubiquitination of β-catenin to suppress metastasis in prostate cancer